Pralsetinib capsules 100 mg/capsule, 120 capsules/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Interstitial lung disease (ILD)/pneumonia: In case of grade 1 or 2 reaction, interrupt LuciPral until response is resolved, then resume at a lower dose. In case of recurrent ILD/pneumonia, permanently discontinue. In case of Grade 3 or Grade 4 reaction, permanently discontinue.
• Blood Pressure: Do not start LuciPral in patients with uncontrolled Blood Pressure. Before starting LuciPral, blood pressure (BP) should be optimized. Blood pressure should be monitored after 1 week and at least monthly thereafter and as clinically indicated. Suspend, reduce the dose, or permanently discontinue LuciPral, depending on the severity.
• Hepatotoxicity: ALT and AST are monitored every 2 weeks for the first 3 months before starting LuciPral, and monthly thereafter, as clinically indicated. Suspend, reduce the dose, or permanently discontinue LuciPral, depending on the severity.
• Bleeding events: permanently discontinue LuciPral for patients with severe or life-threatening bleeding.
• Tumor lysis syndrome: at-risk patients are closely monitored and treated as clinically indicated.
• Risk of impaired wound healing: discontinue use of LuciPral at least 5 days prior to elective surgery. Do not use for at least 2 weeks after major surgery until the wound has fully healed. The safety of returning to LuciPral after resolution of wound healing complications has not been determined.
• Embryo-fetal toxicity: May cause harm to the fetus. Women of childbearing potential are advised to be aware of the potential risks to the fetus and to use effective non-hormonal contraception.

Medication risks

Adverse Reactions
The most common adverse effects (≥ 25%) were constipation, Blood Pressure, fatigue, musculoskeletal pain, and diarrhea. The most common grade 3-4 laboratory abnormalities (≥ 2%) are lymphopenia, neutropenia, hemoglobin decreased, phosphate decreased, calcium decreased (corrected), sodium decreased, aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, thrombocytopenia, and alkaline phosphatase increased.